Kretzler Annette, Molls Michael, Gradinger Reiner, Lukas Peter, Steinau Hans-Ullrich, Würschmidt Florian
Department of Radiotherapy and Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Germany.
Strahlenther Onkol. 2004 Jun;180(6):365-70. doi: 10.1007/s00066-004-1191-8.
Evaluation of treatment outcome after intraoperative radiotherapy (IORT) +/- external-beam irradiation (EBRT) in patients with localized soft tissue sarcoma of the extremity at high risk for local recurrence after limb-sparing surgery.
28 patients treated between 1989 and 1999 were evaluated retrospectively. Patients presented with locally recurrent (n = 17), T2 (n = 20), high-grade (n = 26), or incompletely resected tumors (n = 11). All patients underwent limbsparing surgery and IORT (median dose of 15 Gy) given either with high-dose-rate brachytherapy or a linear accelerator. 25 patients received additional EBRT with a mean of 50.6 Gy (range: 30.6-60 Gy). The mean follow-up time was 4.3 years (95% confidence interval [CI]: 3.0-5.6 years).
The 5-year overall and distant disease-free survival rates were 66% and 54%, respectively. The overall actuarial recurrence rate after 5 years is 16% (95% CI: 1%, 31%). The crude rate after 8 years is 18%. Surgical margin status, primary versus recurrent tumor and tumor stage did not show any statistically significant influence (univariate analysis) on local recurrence rates. Patients with T1 tumors exhibited a borderline significant (p = 0.053) better distant disease-free survival (83%) compared to T2 tumors (43%). Five (24%) grade 3-4 late side effects were observed.
In patients with high-risk soft tissue sarcomas, IORT +/- EBRT after limb-preserving surgery achieves high local control rates. The risk of normal tissue toxicities is comparable to conventional limb-sparing treatment.
评估肢体局限性软组织肉瘤患者在保肢手术后局部复发风险高时,术中放疗(IORT)±外照射放疗(EBRT)后的治疗效果。
对1989年至1999年间治疗的28例患者进行回顾性评估。患者表现为局部复发(n = 17)、T2期(n = 20)、高级别(n = 26)或肿瘤切除不完全(n = 11)。所有患者均接受了保肢手术和IORT(中位剂量为15 Gy),采用高剂量率近距离放疗或直线加速器进行。25例患者接受了额外的EBRT,平均剂量为50.6 Gy(范围:30.6 - 60 Gy)。平均随访时间为4.3年(95%置信区间[CI]:3.0 - 5.6年)。
5年总生存率和无远处疾病生存率分别为66%和54%。5年后的总精算复发率为16%(95% CI:1%,31%)。8年后的粗复发率为18%。手术切缘状态、原发肿瘤与复发肿瘤以及肿瘤分期对局部复发率均未显示出任何统计学上的显著影响(单因素分析)。与T2肿瘤(43%)相比,T1肿瘤患者的无远处疾病生存率有临界显著性差异(p = 0.053),为83%。观察到5例(24%)3 - 4级晚期副作用。
对于高危软组织肉瘤患者,保肢手术后IORT±EBRT可实现较高的局部控制率。正常组织毒性风险与传统保肢治疗相当。